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ABSTRACT The leukocyte common antigen (CD45) is an
abundant lymphocyte surface antigen that has been reported to
be involved in signaling through the T-cell antigen receptor.
CD45 is a transmembrane protein-tyrosine-phosphatase. An
internal segment comprises two domains each of which is
homologous to other protein-tyrosine-phosphatases; the extra-
cellular segment has the hallmarks of a ignd-binding motif.
Since tyrosine phosphorylation is an early signal resulting from
stimulation of the T-cell antigen receptor and CD45 is required
for proper activation through the receptor, we explored
whether CD45 might be regulated by tyrosine phosphorylation.
Treatment of a T-cell leukemia line (Jurkat) with either
phytohemagglutinin or anti-CD3 antibodies induced phosphor-
ylation of tyrosine residues in CD45; treatment with phorbol
12-myristate 13-acetate did not. Phosphorylation of CD45 was
transient, disappearing within 40 min after phytohemaggluti-
nin treatment. The requirement for stringent conditions of
phosphatase inhibition suggests that CD45 is capable of au-
todephosphorylation in vivo. These observations support recent
reports indicating CD45 is involved in an early step in the T-cell
activation cascade. They also suggest that phosphoryla-
tion/dephosphorylation of tyrosine residues in CD45 should be
explored further as a possible regulatory mechanism.
The role of protein-tyrosine kinases (PTKs) in signal trans-
duction and cell proliferation (1, 2) attests to the importance
of phosphorylation of tyrosine residues, despite the obser-
vation that it accounts for only a small percentage of the total
phosphate associated with protein in vivo (3). Strict control
over the level of phosphorylation, particularly of tyrosine
residues, seems to be necessary for normal cell growth, since
overexpression or mutation of endogenous PTKs often leads
to transformation ofthe affected cells (2). Dephosphorylation
by protein-tyrosine-phosphatases (PTPases) provides one
mechanism for controlling the level of phosphotyrosine. The
recent discovery of at least 15 PTPases (4, 5), as well as
identification of 27 different PCR fragments from Styela
plicata (6) that are homologous to known PTPase domains,
suggests that the PTPases are as diverse and as important for
control of phosphotyrosine levels as are the PTKs. As an
example, the protein-serine/threonine kinase p34cdc2, which
controls the transition from the G2 phase ofthe cell cycle into
mitosis, is activated by the dephosphorylation of a tyrosine
residue in its ATP-binding site (7). In addition, a PTPase has
been identified as the pathogenic agent of the plague (8),
while another is encoded by the vaccinia viral genome (9).
Such observations suggest that PTPases will be identified as
critical elements in the control of a diverse array of funda-
mental cellular processes. Thus, characterization of the
mechanisms that control their activity will be an essential
step in understanding the physiological role of reversible
protein tyrosine phosphorylation.
The stimulation ofT lymphocytes by antigen, by antibodies
to the T-cell antigen receptor (TCR)/CD3 complex, or by
mitogenic lectins results in hydrolysis of inositolphospholip-
ids, mobilization of Ca2l from intracellular stores, cytokine
secretion, and proliferation (10-12). There is substantial
evidence that the TCR-mediated activation ofT cells induces
a rapid increase in PTK activity that leads to increased
phosphorylation of the ; chain of the TCR (13) and several
other intracellular targets (14, 15). The PTKs p56lck (16),
which is associated with the CD4 or CD8 cell surface anti-
gens, and p59fyn (17, 18), which may be associated with the
TCR, may be involved in these early tyrosine phosphoryla-
tion events, but their precise roles have not yet been estab-
lished.
In fact, recent findings indicate that a transmembrane
PTPase, CD45 (19, 20), is required for induction of the early
tyrosine phosphorylation of proteins and for effective cou-
pling of the TCR to the phosphatidylinositol pathway (21),
suggesting that antigen-induced dephosphorylation is re-
quired for activation ofPTKs. The involvement ofboth PTKs
and PTPases in T-cell activation pathways raises the possi-
bility of direct regulatory interactions between the two op-
posing activities. An example of this type of regulation is
provided by CD45 and p561ck, where dephosphorylation of
the kinase in vitro results in activation (22). Given the
requirement for both PTPases and PTKs for complete T-cell
activation, we sought evidence that CD45 might be directly
regulated by the PTKs. Using phospho amino acid analysis
and anti-phosphotyrosine antibodies, we have demonstrated
that CD45 itself is phosphorylated on tyrosine residues in
vivo following stimulation with either the mitogenic lectin
phytohemagglutinin (PHA) or anti-CD3 antibodies. Our find-
ings show that CD45 in T cells is a target for an as yet
unknown PTK. This observation suggests that reversible
phosphorylation of tyrosine residues in CD45 may be of
regulatory significance.
MATERIALS AND METHODS
Cell Cultures and Extractions. The human acute T-cell
leukemia cell line Jurkat (clone E6-1, ATCC TIB 152), was
grown at 37°C in RPMI 1640 with 10% newborn calf serum.
Before treatment, the cells were concentrated to 1-5 x 107
cells per ml in 10 ml of RPMI 1640 medium. The cells were
stimulated with either PHA-L (5 ,ug/ml; Sigma), phorbol
12-myristate 13-acetate (PMA, 5 ,ug/ml; Sigma), both PHA
and PMA, or anti-CD3 antibody (G19-4, 5 ,ug/ml). The
PTPase inhibitor phenylarsine oxide (PhAsO, Sigma), dis-
solved in dimethyl sulfoxide, was added to the cells 10 min
Abbreviations: PHA, phytohemagglutinin; PhAsO, phenylarsine ox-
ide; PMA, phorbol 12-myristate 13-acetate; PTK, protein-tyrosine
kinase; PTPase, protein-tyrosine-phosphatase; TCR, T-cell antigen
receptor; PVDF, poly(vinylidene difluoride).
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before extraction with buffer A [1% (vol/vol) Nonidet
P-40/10 mM EDTA/50 mM Tris HCI, pH 7.5/1 mM phenyl-
methanesulfonyl fluoride/1 mM benzamidine/0.001% apro-
tinin/0.001% pepstatin/0.001% leupeptin] containing 100AM
iodoacetate and 100 AM PhAsO and titrated to pH 1.5 with
HCl. The extracts were homogenized and insoluble cell
debris was pelleted at 10,000 rpm in a Sorvall SS-34 rotor.
32p Labeling. Jurkat cells were washed for 30 min in
phosphate-free medium and then centrifuged and resus-
pended to a concentration of 1-5 x 108 cells per ml in 2 ml
of phosphate-free medium. The cells were incubated with
KH232P04 (500 pCi/ml; 1 ACi = 37 kBq) for 4 hr at 370C;
stimulation and extraction were as described above.
Immunoprecipitations and Immunoblotting. Fifty micro-
grams of the appropriate antibody was incubated with cell
extracts (adjusted to pH 7.5) for 2-12 hr at 40C. Protein
A-Sepharose (5 mg, Pharmacia) was used to precipitate the
primary antibody and the proteins bound to it. The precipi-
tates were washed twice in 10 ml of buffer A, twice in 10 ml
of buffer A/500 mM NaCl, and twice in 10 ml of 50 mM
TrisHCI, pH 7.5/200 ,M Na3VO4/100 ,M PhAsO. The
samples were solubilized in SDS sample buffer and subjected
to electrophoresis in an SDS/7.5% polyacrylamide gel (23).
Following transfer to poly(vinylidene difluoride) (PVDF)
membrane (Millipore), blots were incubated with anti-CD45
antibody (monoclonals 9.4 and Gap 8.3 or polyclonal 7671) or
anti-phosphotyrosine monoclonal antibody 4G-10 (Upstate
Biotechnology). The blots were developed with goat anti-
mouse or goat anti-rabbit secondary antibody complexed to
horseradish peroxidase (Vector Laboratories).
Phospho Amino Acid Analysis. Solubilized anti-CD45 im-
munoprecipitates prepared from 32P-labeled cells were sub-
jected to a second round of immunoprecipitation by first
precipitating proteins with acetone (to remove SDS) and
repeating the immunoprecipitation and wash procedure with
a different anti-CD45 antibody. After SDS/PAGE and im-
munoblotting, the bands detected with anti-CD45 antibody
were excised for phospho amino acid analysis (24).
PTPase Assays. CD45 was immunoprecipitated from ex-
tracts of Jurkat cells lysed in 1% Nonidet P-40/50 mM
Hepes/0.1% 2-mercaptoethanol/100 mM NaCI. The precip-
itates were washed four times in the same buffer without
2-mercaptoethanol, to remove any residual reducing agent.
The reducing agents and PhAsO were added to separate
aliquots as indicated before PTPase assay as described pre-
viously (25).
In Vitro Phosphorylation. CD45 was phosphorylated in
vitro by v-abl (gift from Curt Diltz) and pp60csrc (Oncogene
Science, Manhasset, NY) with the protocol supplied by
Oncogene Science. In brief, the appropriate kinase was
incubated for 10 hr at 30°C in 50 mM Hepes, pH 7.5/0.1 mM
EDTA/0.15% Brij 35/0.1% 2-mercaptoethanol/0.01% bo-
vine serum albumin/10 mM MgCl2/0.1 mM ATP (200 ,uCi of
[y-32P]ATP per ml). Na3VO4 (1 mM) was included in the
assay buffer to prevent autodephosphorylation. Phosphory-
lation was detected by autoradiograms of Western blots
performed for each assay.
RESULTS AND DISCUSSION
The discovery of potent inhibitors of the PTPases (26), most
notably orthovanadate (Na3VO4), has facilitated the detec-
tion of phosphotyrosine in proteins. Pretreatment of cells
with PhAsO has been shown to enhance recoveries of phos-
photyrosine (27) but to have no apparent effect on the activity
of two PTKs, p56Ick and p59fyn, in vitro (15). CD45 was
observed to be phosphorylated by v-abl and pp60Cv s in vitro,
but only in the presence ofPTPase inhibitors such as Na3VO4
(data not shown), suggesting that CD45 can autodephospho-
rylate in vitro. Inclusion of PTPase inhibitors in the extrac-
tion solvent was not sufficient to allow detection of signifi-
cant levels of phosphotyrosine in CD45 from PHA-treated
Jurkat cells (Fig. 1, lanes A and B). However, phosphoty-
rosine was clearly observed in CD45 when T cells were
pretreated with PhAsO prior to PHA stimulation and extrac-
tion (lane D), suggesting that a PTPase inhibitor is required
to block autodephosphorylation in vivo as well. These results
indicate that phosphorylation ofCD45 on tyrosine residues is
induced by PHA treatment.
To explore the mechanism by which PhAsO enhances the
detection of phosphotyrosine, we examined the effect of
PhAsO on isolated CD45. Since the PTPases are inhibited by
reagents that modify thiols (28) and PhAsO reacts with vicinal
sulfhydryls as well as sulfhydryls proximal to hydroxyls or
carboxyls (29), PhAsO may inhibit the PTPases in this
manner. Garcia-Morales et al. (15) have reported that CD45
is inhibited by PhAsO in the absence of reducing agents.
However, the activity of CD45 is lost rapidly in the absence
of reducing agents even without PhAsO present (Fig. 2). In
the presence of 0.1% 2-mercaptoethanol, CD45 retains its
activity and is not inhibited by PhAsO (Fig. 2). Apparently,
2-mercaptoethanol can compete with CD45 for PhAsO. Since
glutathione (=5 mM) is the major intracellular reducing agent
(30), we tested its ability to stabilize CD45 in vitro and to
interfere with inhibition by PhAsO. Glutathione does protect
the activity of CD45, but it does not prevent inhibition of
CD45 by PhAsO (Fig. 2). Thus, these data suggest that
PhAsO can inhibit CD45 in vivo.
Fig. 3 demonstrates that the anti-phosphotyrosine antibod-
ies recognize phosphotyrosine and not some other feature of
CD45. Two bands were observed on a Western blot with
anti-phosphotyrosine monoclonal antibody; these corre-
spond to those detected by anti-CD45 antibodies (Fig. 1).
Binding of anti-phosphotyrosine antibody to CD45 was com-
pletely blocked by phosphotyrosine, whereas phosphoserine
and phosphothreonine were without effect. The anti-
phosphotyrosine antibody no longer recognized CD45 after
pretreatment of the Western blots with active CD45. Thus
CD45, which is specific for phosphotyrosine residues in vitro
(31), is capable of dephosphorylating the denatured CD45
molecule. These controls demonstrate that the anti-
phosphotyrosine antibody specifically detects phosphoty-
rosine in CD45. Furthermore, phospho amino acid analysis
confirmed the presence of phosphotyrosine in twice-
immunoprecipitated CD45 from PHA-treated cells (Fig. 3B)
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FIG. 1. Pretreatment of cells with PhAsO is required for optimal
detection of phosphotyrosine in CD45. Jurkat cells (5 x 107) were
treated with PHA (5 ug/ml) and extracted as indicated. CD45 was
immunoprecipitated with monoclonal antibody 9.4 and analyzed by
SDS/PAGE. Protein bands were then transferred to PVDF mem-
brane and immunoblotted with an anti-phosphotyrosine antibody.
Lane A, 200 ,IM Na3VO4/buffer A; lane B, extraction with PTPase
inhibitor buffer (buffer A/200 jiM Na3VO4/100 AM iodoacetic acid/
100,uM PhAsO; titrated to pH 1.5 with HCl); lane C, 37 ,uM PhAsO
added 10 min before extraction (concurrent with PHA treatment)
with buffer A/200 jLM Na3VO4; lane D, 37 ,uM PhAsO pretreatment
(as in lane C), and extraction with PTPase inhibitor buffer.
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FIG. 2. Effects ofPhAsO on CD45 in the presence ofglutathione.
PTPase activity of CD45 precipitated from 5 x 106 Jurkat cells was
measured to determine the effect of PhAsO on CD45 activity in the
presence of 14.3 mM (0.1%, vol/vol) 2-mercaptoethanol (2-ME) or
various concentrations of glutathione. CD45 was immunoprecipi-
tated and washed extensively in 50 mM Hepes, pH 7.2/0.1% Triton
X-100 to remove any residual reducing agent. The indicated reducing
agents were added back to separate aliquots of CD45, followed by
addition of PhAsO, as indicated. Activity was measured relative to
the activity of CD45 in 14.3 mM 2-ME without PhAsO present.
and established the lack of phosphotyrosine in CD45 from
untreated cells.
To probe the physiological significance of this phosphor-
ylation, a time course of phosphorylation of CD45 was
examined. Phosphotyrosine was observed in CD45 within 5
min of PHA treatment and was no longer detected after 40
min (Fig. 4). Similar results were observed following treat-
ment ofthe cells with anti-CD3 antibodies and with a mixture
ofPHA andPMA (data not shown); however, PMA treatment
alone did not lead to detectable phosphorylation of CD45 on
tyrosine residues. The effect ofthis phosphorylation on CD45
activity is not readily assessed since isolation of phospho-
rylated CD45 requires inhibition of activity. To address the
possibility that PHA has a direct effect on CD45, the PTPase
activity of antibody-purified CD45 was assayed in the pres-
ence and absence ofPHA. No significant effect ofPHA 5-50
.ug/ml on PTPase activity toward myelin basic protein or
reduced, carboxymethylated lysozyme was observed (data
not shown). These data indicate that both anti-CD3 antibod-
ies and PHA induce a rapid, yet transient, activation ofaPTK
that phosphorylates CD45 in vivo. Because of the necessity
for pretreatment of cells with a PTPase inhibitor, the amount
of 32P incorporated following stimulation (Fig. 4) cannot be
used to obtain any physiologically significant estimate of the
extent of CD45 phosphorylation. However Fig. 4 does pro-
vide a time course of the relative activity of PTK(s) toward
CD45 and suggests that this activation is transient.
PHA binds to the TCR as well as other surface antigens,
including CD3, CD2, and CD45 (11). Activation of T cells
with PHA induces proliferation, stimulates synthesis of in-
terleukin 2 and its receptor (11), and rapidly increases PTK
activity toward several substrates. Although PHA may in-
teract with multiple cell surface antigens, T-cell responses to
PHA resemble those observed with agents that act directly
upon the TCR complex. T cells treated with PTK inhibitors
(13) and T cells lacking CD45 (21) fail to elicit phosphatidy-
linositol-derived second messengers, implying that both ki-
nases and phosphatases play an active role in T-cell activa-
tion. In fact, Koretzky et al. (32) have demonstrated that
FIG. 3. PHA-induced phosphorylation of CD45. (A) Western
blots of extracts of PHA-stimulated Jurkat cells. Jurkat cells were
activated and extracted as in Fig. 2. Each lane contained the protein
immunoprecipitated, with monoclonal antibody 9.4, from ='5 x 107
Jurkat cells. Four identical immunoprecipitates were subjected to
electrophoresis and transferred to PVDF membrane. The lanes were
separated in order to assess the specificity ofthe antibody by several
types ofcontrols. Lane 1, anti-phosphotyrosine antibody; lane 2; blot
was pretreated for 10 min at 3TC with 50 1Lg of active CD45, then
immunoblotted with anti-phosphotyrosine antibody; lane 3, anti-
phosphotyrosine antibody plus 5 mM phosphoserine and 5 mM
phosphothreonine; lane 4, anti-phosphotyrosine antibody and 1 mM
phosphotyrosine. (B) Phospho amino acid analysis of CD4S isolated
from PHA- and PMA-treated Jurkat cells. Jurkat cells (5 x 108) were
32P-labeled and then treated with PHA (5 plg/ml), PMA (5 .g/ml),
and PhAsO (37 t&M) 10 min prior to extraction in PTPase inhibitor
buffer (see Fig. 1). The extracts were twice immunoprecipitated as
described in Materials and Methods, first with anti-CD45 monoclo-
nal antibody 9.4 then with anti-CD45 polyclonal antibody 7671. The
washed pellet was subjected to electrophoresis and transferred to
PVDF. Two bands detected by immunoblotting with another CD45-
specific monoclonal antibody, Gap 8.3, were excised for phospho
amino acid analysis. Positions of phospho amino acid standards (S,
phosphoserine; Y, phosphotyrosine) as detected by ninhydrin stain-
ing are indicated.
CD45 appears to be required for activation of at least one
PTK during T-cell activation. The transient phosphorylation
ofCD45 was observed following stimulation with eitherPHA
or anti-CD3 antibodies but not with phorbol ester treatment.
Thus we conclude that CD45 is a physiologically relevant
substrate for a T-cell PTK and that the nature of the stimulus
that causes phosphorylation of CD45 is consisent with its
direct involvement in signaling through the TCR complex.
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FIG. 4. Time course for PHA-induced phosphorylation of CD45.
Aliquots of 5 x 108 cells were treated with PhAsO 10 min before
extraction, independent ofthe time of activation. PHA (5 gtg/ml) was
added 5, 15, or 40 min before extraction. Western blots of anti-CD45
immunoprecipitates were immunostained with anti-phosphotyrosine
antibodies.
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The requirement for both PTKs and PTPases in the early
stages of T-cell activation, the ability of CD45 to activate
p56 ck by dephosphorylation in vitro, and now the observa-
tion that CD45 is phosphorylated and then rapidly dephos-
phorylated (in the absence of inhibitors) during T-cell acti-
vation raise the intriguing possibility that the PTKs and
PTPases actually cooperate to transduce a signal. Tradition-
ally it has been proposed that the kinase transduces a signal
and then eventually the phosphatase shuts it off. This model
is gradually giving way to one in which there is a more
dynamic relationship between the PTKs and PTPases where
both are required to transduce a signal and there is continual
bilateral feedback between the two processes.
We are grateful to E. H. Fischer for illuminating discussions, Curt
Diltz for the PTPase substrates, and Mary Valentine and E. A. Clark
for providing antibodies for this study. This work was funded by
National Institutes of Health Grants GM15731 (to K.A.W.) and
AM07902 (to E. H. Fischer) and by funds from the Muscular
Dystrophy Association (to E. H. Fischer). D.R.S. was supported by
National Research Service Award GM07270.
1. Ullrich, A. & Schlessinger, J. (1990) Cell 61, 203-212.
2. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B.,
Graziani, A., Kapeller, R. & Soltoff, S. (1991) Cell64, 281-302.
3. Hunter, T. & Cooper, J. A. (1986) in The Enzymes, eds. Boyer,
P. D. & Krebs, E. G. (Academic, Orlando, FL), Vol. 17, pp.
192-248.
4. Kreuger, N. X., Streuli, M. & Saito, H. (1990) EMBO J. 9 (10),
3241-3252.
5. Fischer, E. H., Charbonneau, H. & Tonks, N. K. (1991) Sci-
ence, in press.
6. Mathews, R. J., Flores, E. & Thomas, M. L. (1991) Immuno-
genetics 33, 33-41.
7. Gould, K. L., Moreno, S., Tonks, N. K. & Nurse, P. (1990)
Science 250, 1573-1576.
8. Guan, K. & Dixon, J. E. (1990) Science 249, 553-556.
9. Guan, K., Broyles, S. S. & Dixon, J. E. (1991) Nature (Lon-
don) 350, 359-362.
10. Gardner, P. (1989) Cell 59, 15-20.
11. Bernabeu, C., Carrera, A. C., De Landazuri, M. 0. &
Sanchez-Madrid, F. (1987) Eur. J. Immunol. 17, 1461-1466.
12. Moretta, A., Ciccone, E., Pantaleo, G., Tambussi, G., Bottino,
C., Melioli, G., Mingari, M. C. & Moretta, L. (1989) Immunol.
Rev. 111, 145-168.
13. June, C. H., Fletcher, M. C., Ledbetter, J. A., Schieven,
G. L., Siegel, J. N., Phillips, A. F. & Samelson, L. E. (1990)
Proc. Natl. Acad. Sci. USA 87, 7722-7726.
14. Patel, M. D., Samelson, L. E. & Klausner, R. D. (1987) J. Biol.
Chem. 262 (12), 5831-5838.
15. Garcia-Morales, P., Minami, Y., Luong, E. & Klausner, R. D.
(1990) Proc. Natd. Acad. Sci. USA 87, 9255-9259.
16. Veillette, A., Bookman, M. A., Horak, E. M. & Bolen, J. B.
(1988) Cell 55, 301-308.
17. Samelson, L. E., Phillips, A. F., Luong, E. T. & Klausner,
R. D. (1990) Proc. Natl. Acad. Sci. USA 87, 4358-4362.
18. Cooke, M. P., Abraham, K. M., Forbush, K. A. & Perlmutter,
R. M. (1991) Cell 65, 281-291.
19. Tonks, N. K., Charbonneau, H., Diltz, C. D., Fischer, E. H.
& Walsh, K. A. (1988) Biochemistry 27, 8695-8701.
20. Charbonneau, H., Tonks, N. K., Walsh, K. A. & Fischer,
E. H. (1988) Proc. Natl. Acad. Sci. USA 85, 7182-7186.
21. Koretzky, G. A., Picus, J., Thomas, M. L. & Weiss, A. (1990)
Nature (London) 346, 66-68.
22. Mustelin, T. & Altman, A. (1990) Oncogene 5, 809-813.
23. Laemmli, U. K. (1970) Nature (London) 227, 680-685.
24. Kamps, M. K. & Sefton, B. M. (1989) Anal. Biochem. 176,
22-27.
25. Tonks, N. K., Diltz, C. D. & Fischer, E. H. (1988) J. Biol.
Chem. 263, 6722-6730.
26. Swarup, G., Cohen, S. & Garbers, D. (1982) Biochem. Biophys.
Res. Commun. 107, 1104-1109.
27. Bernier, N., Laird, D. M. & Lane, N. D. (1987) Proc. Nat!.
Acad. Sci. USA 84, 1844-1848.
28. Tonks, N. K., Diltz, C. D. & Fischer, E. H. (1988) J. Biol.
Chem. 263, 6731-6737.
29. Hannestad, U. & Sorbo, B. (1980) J. Chromatogr. 200, 171-
177.
30. Meister, A. & Anderson, M. E. (1983)Annu. Rev. Biochem. 52,
711-760.
31. Tonks, N. K., Diltz, C. D. & Fischer, E. H. (1990) J. Biol.
Chem. 265, 10674-10680.
32. Koretzky, G. A., Picus, J., Schultz, T. & Weiss, A. (1991)
Proc. Natl. Acad. Sci. USA 88, 2037-2041.
Immunology: Stover et aL
